Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

2500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-15

Study Completion Date

2038-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the prevention of TB in human immunodeficiency virus (HIV)-infected individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

NCT01404312

Tuberculosis HIV Infections

COMPLETED PHASE3

A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

NCT07124559

Tuberculosis

NOT_YET_RECRUITING PHASE1/PHASE2

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029

Latent Tuberculosis

RECRUITING PHASE2/PHASE3

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

NCT00023452

Tuberculosis

COMPLETED PHASE3

Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

NCT05118490

HIV Seropositivity Tuberculosis Household Contact

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multicenter, randomized, open-label, phase III clinical trial comparing a 4-week daily INH/RPT regimen (1HP) to a 12-weekly INH/RPT (3HP) for the treatment of LTBI in HIV-infected participants without evidence of active TB. The primary objective will be efficacy of active TB prevention. The study will also assess safety and tolerability of the regimens, adherence to the treatments, and patterns of antibiotic resistance among Mycobacterium tuberculosis (MTB) isolates in participants who fail on these prophylactic regimens.

Under this study, there is one substudy entitled, "Pharmacokinetic study of rifapentine, dolutegravir, and tenofovir alafenamide in HIV-infected individual with latent tubersulosis infection". There will be a subgroup of patients who will participate in this pharmacokinetic study of rifapentine and dolutegravir (DTG) / tenofovir alafenamide (TAF). Randomization is based on cluster of differentiation 4 (CD4) categories : \< 200, 200-350, \> 500 cells/mm3 and VL \<50 or \>50 copies/ml.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-infected Participants With Latent TB Infection in High TB Burden Country

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study is a multicenter, randomized, open-label, phase III clinical trial comparing a 4-week daily INH/RPT regimen (1HP) to a 12-weekly INH/RPT (3HP) for the treatment of LTBI in HIV-infected participants without evidence of active TB.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1HP

4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)

Group Type EXPERIMENTAL

Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

Intervention Type DRUG

Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

3HP

12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)

Group Type ACTIVE_COMPARATOR

Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

Intervention Type DRUG

Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

Intervention Type DRUG

Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Documented HIV-1 infection by standard HIV test or plasma HIV-1 RNA viral load and received ART within 12 months. Participants received ART more than 12 months would be allowed if CD4 cell counts is less than 350 cells/mm3
2. 18 years and older
3. Evidence of latent TB infection, either by TST ≥5 mm or positive interferon gamma release assay (IGRA) or history of close contact with active pulmonary TB\* within 3 months prior entry visit or residing in a high TB burden area\*\* NOTE \* close contact is referred to person living/sharing in the same room with active pulmonary TB participants for \> 4 hours/day

\*\* high TB burden areas are defined as areas with an estimated or reported TB prevalence of 100 to 300/100,000, according to the WHO. Thailand is included in high TB burden areas.
4. Laboratory values obtained within 30 days prior to entry

* Absolute neutrophil count (ANC) \>750 cells/mm3
* Hemoglobin \>7.4 g/dL
* Platelet count \>50,000/mm3
* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) \<3x upper limit of normal (ULN)
* Total bilirubin \<2.5 X ULN
5. Chest radiograph or chest computed tomography (CT) scan without evidence of active tuberculosis, unless one has been performed within 90 days prior to entry.
6. Female participants who are participating in sexual activity that could lead to pregnancy must agree to use one reliable non-hormonal form of contraceptive (i.e., condoms, IUD, diaphragm) during RPT treatment and contraception should be remain to 6 weeks post RPT NOTE Female participants who are not of reproductive potential or whose male partner(s) have undergone successful vasectomy with documented azoospermia or have documented azoospermia are eligible without requiring the use of contraceptives. Participant-reported history is acceptable documentation of menopause, hysterectomy, or bilateral oophorectomy or bilateral tubal ligation.
7. All participants must agree not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization) while receiving RPT and for 6 weeks after stopping this drug.
8. Body weight \> 40 kg
9. Ability and willingness of participant to provide informed consent

Exclusion Criteria

1. Treatment for active or latent TB (pulmonary or extrapulmonary) within 2 years prior to study entry or presence of any confirmed or probable active TB at screening.
2. History of Isoniazid (INH) or Rifampicin (RIF)/Rifabutin (RFB) resistant TB at any time prior to study entry or known exposure to INH or RIF/RFB resistant TB (e.g., household member of a person with MDR or XDR TB) at any time prior to study entry.
3. Treatment for \>14 consecutive days with a rifamycin or \>30 consecutive days with INH at any time during the 2 years prior to enrollment.
4. Current or planned use of protease inhibitor-based ART.
5. Currently on a salvage ART regimen, defined as a regimen started due to confirmed HIV virologic failure on a prior ART regimen or due to known HIV drug resistance.
6. History of liver cirrhosis at any time prior to study entry.
7. Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or light stools within 90 days prior to entry.
8. Diagnosis of porphyria at any time prior to study entry.
9. Peripheral neuropathy ≥Grade 2 according to the Division of AIDS (DAIDS) Toxicity Table, within 90 days prior to study entry.
10. Known allergy/sensitivity or any hypersensitivity to components of study drug(s) or their formulation.
11. Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
12. Acute or serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry.
13. Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No